However one study found that IDO1 expression in the tumor microenvironment and normal tissue in NSCLC was not significantly different (Long et al., 2019), which may be one of the reasons for the lack of clinical benefit of IDO1 inhibitors. Here, IDO1 is linked to non-small cell lung carcinoma.